Advancing a platform of a novel drug class, redox-active metalloporphyrins, for the treatment of cancer patients.



BioMimetix, founded in 2013, is a pioneering small biotechnology firm at the forefront of transforming the landscape of cancer treatment with our novel compound, BMX-001. Leveraging groundbreaking research, we have developed a redox-active compound poised to revolutionize cancer treatment.

With a strategic focus on effective resource management, our company has demonstrated exceptional financial acumen over the past decade and completion of exciting Phase 2 data.

New drug class preparing for Phase 3 pivotal trial in high-grade glioma

Demonstrated clinical efficacy in multiple oncology indications

Platform drug transforming chemoradiation in multiple cancers

Unique dual action
tumor killing
and protects healthy tissue

FDA Breakthrough Therapy designation


Unique dual action both enhances tumor killing and protects healthy tissue.
Platform potential for multiple cancer types.

Share This Webpage

Share this page with your friends!